CD276 and benign prostatic hyperplasia: In addition, Yuan et al. [11] found that the expression level of CD276 in a prostate cancer group was significantly higher compared with that in the associated benign prostatic hyperplasia group, and knockdown of CD276 led to a marked reduction in the migratory and invasive capabilities of prostate cancer cells, thereby demonstrating that CD276 has an important role in the progression of prostate cancer.